Table 3.
Sub-G0/G1-fraction of HT1376, T24, and 5637 urinary bladder-cancer cell lines, after treatment with cisplatin and sunitinib malate, in isolation or combined. Sub-G0/G1 values are mean ± SD of the three independent experiments.
| Sub-G0/G1-fraction | |||
|---|---|---|---|
| HT1376 | T24 | 5637 | |
| Control | 13.1 ± 4.8 | 13.5 ± 4 | 8.6 ± 4.1 |
| Cisplatin (3 μM) | 13.7 ± 1.1 | 22.6 ± 3.3 | 26.4 ± 2.1 |
| Sunitinib malate (1 μM) | 35.9 ± 7.4 | 12.9 ± 1.2 | 46.4 ± 5.2 |
| Sunitinib malate (2 μM) | 36.5 ± 3.2 | 13.6 ± 2.4 | 44.2 ± 1.8 |
| Sunitinib malate (4 μM) | 44.2 ± 5.4 | 18.2 ± 3.4 | 35.3 ± 3.6 |
| Cisplatin (3 μM) + sunitinib malate (1 μM) | 24.5 ± 0.8 | 22.8 ± 6 | 33.4 ± 4.4 |
| Cisplatin (3 μM) + sunitinib malate (2 μM) | 47.4 ± 6.6 | 28.8 ± 5.2 | 34.5 ± 3.6 |
| Cisplatin (3 μM) + sunitinib malate (4 μM) | 49.3 ± 2.9 | 31.2 ± 5.7 | 34 ± 2.2 |
SD: standard deviation.